Kevin Koch sold $287k of EWTX
President and CEO at Edgewise Therapeutics, Inc.. 9,536 shares at an average of $30.13, traded Feb 5, 2025, filed Feb 7, 2025.
Score components
- +25RoleCEO
- +14Trade size$287k at market
- +10Share of holdings soldSold 41% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001562180-25-001025, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 5, 2025 | MOption exercise Common Stock10b5-1 | +8,636 | $0.18 | $1,554 | 23,114 | Feb 7, 2025 |
| Feb 5, 2025 | SOpen-market sale Common Stock10b5-1 | -8,636 | $30.03 | $259k | 14,478 | Feb 7, 2025 |
| Feb 6, 2025 | MOption exercise Common Stock10b5-1 | +900 | $13.11 | $12k | 15,378 | Feb 7, 2025 |
| Feb 6, 2025 | SOpen-market sale Common Stock10b5-1 | -900 | $31.13 | $28k | 14,478 | Feb 7, 2025 |
| Feb 5, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,636 | $0.00 | $0 | 42,545 | Feb 7, 2025 |
| Feb 6, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -900 | $0.00 | $0 | 41,645 | Feb 7, 2025 |
Related signals
Other insiders at Edgewise Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | Edgewise Therapeutics, Inc. | Joanne M. Donovan CMO | $685k 21,338 shares | -69% | |
| 33Weak | Edgewise Therapeutics, Inc. | Joanne M. Donovan CMO | $507k 16,358 shares | -63% | |
| 25Weak | Edgewise Therapeutics, Inc. | Badreddin Edris director | $3.4M 115,471 shares | -85% | |
| 45Moderate | EWTXbuy Edgewise Therapeutics, Inc. | Jonathan C Fox director | $199k 10,700 shares | +82% | |
| 45Moderate | EWTXsell Edgewise Therapeutics, Inc. | Alan J Russell Chief Scientific Officer | $2.1M 100,000 shares | -81% | |
| 60Notable | Edgewise Therapeutics, Inc. | Alan J Russell Chief Scientific Officer | $1.5M 100,000 shares | -81% | |
| 22Weak | Edgewise Therapeutics, Inc. | R Michael Carruthers Chief Financial Officer | $19k 1,428 shares | -2% | |
| 21Weak | Edgewise Therapeutics, Inc. | Behrad Derakhshan Chief Business Officer | $33k 2,491 shares | -10% | |
| 26Weak | Edgewise Therapeutics, Inc. | Joanne M. Donovan CMO | $38k 2,862 shares | -10% | |
| 40Moderate | Edgewise Therapeutics, Inc. | Kevin Koch President and CEO | $107k 7,972 shares | -21% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.